CD274 and esophageal squamous cell carcinoma: Prior economic evidences indicated that PD-1 inhibitors were potentially sensitive to PD-L1-positive ESCC patients, with higher survival benefits and health outcomes compared with the overall population (13, 16, 31, 36, 37).